ERBB2 and breast carcinoma: A phase 2 trial (plasma MATCH trial) of treatment selection with ctDNA mutations in breast cancer showed the efficacy of neratinib for ERBB2 mutations and capivasertib for AKT1 mutations in ctDNA, indicating the usefulness of examining genetic mutations in ctDNA.